Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03800407
Other study ID # IRB201801820 TB/HIV - N
Secondary ID 2R01HD0717795R01
Status Recruiting
Phase
First received
Last updated
Start date January 28, 2019
Est. completion date November 30, 2024

Study information

Verified date May 2024
Source University of Florida
Contact Awewura Kwara, MD
Phone 3522739501
Email awewura.kwara@medicine.ufl.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Efavirenz (EFV)-based antiretroviral therapy (ART) remains the preferred regimen in human immunodeficiency virus (HIV)-infected children aged 3 years or older on rifampin-containing antituberculosis (anti-TB) therapy. This is because drug interactions between first-line anti-TB therapy with protease inhibitors (PIs) are more severe to adjust for, and interactions with integrase strand transfer inhibitors (INSTIs) are not well studied in that age group. Although, current weight-based EFV dosing recommendation is not optimal in some children, pharmacokinetic-treatment response (PK-PD) data to guide optimal dosing of EFV during concurrent rifampin-containing therapy in children is very limited. The study team propose that EFV concentrations outside the optimal therapeutic range in children will be associated with virologic failure due to lack of efficacy because of low concentrations or increased central nervous system (CNS) toxicities from high concentrations leading to poor medication adherence. The study will determine virological suppression rates in HIV-infected children with and without TB coinfection treated with standard efavirenz-based therapy and examine the factors contributing to poor virologic response.


Description:

In a previous study, the study team found that first-line anti-TB therapy had minimal effect on EFV pharmacokinetics (PK) at the population level, but children with TB/HIV coinfection on anti-TB therapy had a trend towards worse virologic outcome compared to those with only HIV infection. Due to the small sample size, the study team were unable to examined the patient factors contributing to the poor virologic response. The study team hypothesized that virologic suppression rates on EFV-based therapy is significantly lower in children with TB/HIV coinfection compared to those with HIV alone. In addition, virologic response will be dependent EFV plasma concentrations, CYP2B6 516 G>T genotype and/or adherence level. This hypothesis is based on the premise that extremes (low and high EFV concentration, respectively) could lead to virologic failure because of lack of efficacy or intolerable side effects leading to poor adherence. The current study will investigate the effect of anti-TB therapy, CYP2B6 genotype and pharmacokinetically determined adherence level on virologic response in children with TB/HIV coinfection treated with EFV-based ART.


Recruitment information / eligibility

Status Recruiting
Enrollment 382
Est. completion date November 30, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 14 Years
Eligibility Inclusion Criteria: - HIV seropositive children with or without active TB - Antiretroviral-naïve to efavirenz and meet criteria for initiation or switch to efavirenz-based ART - Are available for follow-up until achievement of a study endpoint like completion of study at 6 months or discontinuation of ART. Exclusion Criteria: - Unable to obtain informed signed consent parent(s) or legal guardian - Have AIDS-related opportunistic infections other than TB - History of acute hepatitis within 30 days of study entry - Persistent vomiting or diarrhea at time of enrolment - Hemoglobin < 6 g/dl, white blood cells < 2500/mm3, serum creatinine > 1.5 mg/dl, aspartate transaminase (AST) and alanine transaminase (ALT) > 2 times upper limit of normal

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational study
Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART

Locations

Country Name City State
Ghana Kwame Nkrumah University of Science and Technology Kumasi

Sponsors (2)

Lead Sponsor Collaborator
University of Florida Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

Ghana, 

Outcome

Type Measure Description Time frame Safety issue
Primary TB coinfection status and HIV RNA < 200 copies/mL on EFV-based ART in HIV-infected children. The proportion of children with TB/HIV coinfection with virological suppression (HIV RNA < 200 copies/mL) on EFV-based ART and anti-TB therapy compared to that in children with only HIV infection on EFV-based therapy. At week 24 of HIV therapy.
Secondary Efavirenz plasma mid-dose concentration and HIV RNA suppression < 200 copies/mL. Relationship between EFV mid-dose concentration and HIV RNA suppression rate in the combined population of HIV-infected children with and without TB coinfection. Up to week 24 of HIV therapy.
Secondary Random efavirenz concentration below the limit of detection (poor ART adherence) and HIV RNA suppression rate. Relationship poor ART adherence and EFV-based ART response in the combined population of HIV-infected children with and without TB coinfection. Up to week 24 of HIV therapy.
Secondary CYP2B6 516G>T genotype status and random efavirenz concentration below the limit of detection (poor ART adherence). Relationship between CYP2B6 516G>T genotype status and likelihood of poor EFV-based ART adherence. Up to week 24 of HIV therapy.
Secondary CYP2B6 516G>T genotype status and HIV RNA suppression < 200 copies/mL. Relationship between CYP2B6 516G>T genotype status and likelihood of HIV RNA suppression. Up to week 24 of HIV therapy.
Secondary TB coinfection status and risk of virological failure on EFV-based ART. Proportion of children with TB/HIV coinfection compared to those with only HIV infection with virological failure (HIV RNA > 1000 copies/mL) at 12 months of EFV-based ART. Up to week 48 of HIV therapy.
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2